Public health agencies have been raising the profile of arthritis…
FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns
Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…
Remembering Etanercept & the Advent of the Biologic Era
As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…
Coverage & Reimbursement Challenges: Updates from the ACR Insurance Subcommittee Chair
The ACR Insurance Subcommittee is working to address specialty pharmacy requirements for in-office treatments, elimination of consultation codes and other coverage and reimbursement challenges.
Are Your Patients at Risk? Advocacy Matters
When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. You can make a difference.
Evaluation & Management Code Changes Set for 2021
Major changes to office and outpatient evaluation and management codes 99201–99205 and 99211–99215 will take effect Jan. 1, 2021.
Washington Legislature Introduces Student Loan Forgiveness Bill
A bill introduced in January in the Washington Legislature would allow pediatric and juvenile rheumatologists to access the state’s loan forgiveness program.
According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA
NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….
In Memoriam: Calvin R. Brown Jr., MD
Calvin R. Brown Jr., MD, of Chicago, passed away Dec. 1, 2019. He was 66 years old. In the course of a medical career, you meet dozens of people who impact you in one way or another. Patients, professors, fellow students, colleagues in your practice—all help shape who we become as a physician. Sometimes, though,…
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…
- « Previous Page
- 1
- …
- 215
- 216
- 217
- 218
- 219
- …
- 811
- Next Page »